Zydus Lifesciences gets WHO INN approval for 'Usnoflast' as recommended name for ZYIL1 Ruchika Sharma2 April 2024 1:30 PM ISTUsnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus.
Zydus Lifesciences gets USFDA nod to begin Phase II clinical trial of ZYIL1 in Parkinson's disease patients Ruchika Sharma18 Dec 2023 12:30 PM ISTZydus has been granted an 'Orphan Drug Designation' by the US FDA for ZYIL1 in treatment of patients with CAPS, a rare auto-inflammatory disease.
Zydus Lifesciences gets CDSCO nod to begin Phase II clinical trial of ZYIL1 in Amyotrophic Lateral Sclerosis patients Ruchika Sharma25 Oct 2023 11:16 AM ISTThe Phase II clinical trial will study safety, tolerability, pharmacokinetics and pharmacodynamics in patients with ALS.
Zydus Lifesciences to present on ZYIL1 at International Congress of Parkinson's Disease and Movement Disorders Ruchika Sharma26 Aug 2023 1:30 PM ISTZYIL1 is a novel oral small molecule NLRP3 inhibitor.
USFDA grants Orphan Drug Designation to Zydus's ZYIL1 for treatment of Cryopyrin Associated Periodic Syndrome Ruchika Sharma21 March 2023 11:29 AM ISTZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates.
Zydus allowed to conduct Phase 2 trial of ZYIL1 in CAPS patients in Australia Ruchika Sharma14 Dec 2021 1:29 PM ISTAhmedabad: Global pharmaceutical company, Zydus has announced that it has received permission to initiate the Phase II (a) clinical study of its...
Zydus Cadila gets DCGI nod for Phase 1 trial of novel molecule ZYIL1 Ruchika Sharma7 Dec 2020 2:22 PM ISTNew Delhi: Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical...
